Monica E Loghin
Overview
Explore the profile of Monica E Loghin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
1340
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Faraj C, McCutcheon I, Gubbiotti M, Perni S, Gule-Monroe M, Akdemir K, et al.
J Neurooncol
. 2025 Mar;
PMID: 40055259
Purpose: Extra-central nervous system metastasis (ECM) from glioblastoma and other high-grade gliomas (HGGs) is exceedingly rare, likely due to central nervous system barriers and the short overall survival (OS) in...
2.
Keam S, Turner N, Kugeratski F, Rico R, Colunga-Minutti J, Poojary R, et al.
Front Immunol
. 2024 Sep;
15:1447021.
PMID: 39247203
Immune checkpoint inhibitors (ICIs) reinvigorate anti-tumor immune responses by disrupting co-inhibitory immune checkpoint molecules such as programmed cell death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4). Although ICIs...
3.
Gregory T, Knight S, Aaroe A, Highsmith K, Janatpour Z, OBrien B, et al.
Neurooncol Pract
. 2024 Jul;
11(4):475-483.
PMID: 39006516
Background: We observed rapid tumor progression following COVID-19 infection among patients with glioblastoma and sought to systematically characterize their disease course in a retrospective case-control study. Methods: Using an institutional...
4.
Kim S, Chu Y, Misoi M, Suarez-Almazor M, Tayar J, Lu H, et al.
Nat Commun
. 2024 Jul;
15(1):5621.
PMID: 38965214
No abstract available.
5.
Kim S, Chu Y, Misoi M, Suarez-Almazor M, Tayar J, Lu H, et al.
Nat Commun
. 2022 Apr;
13(1):1970.
PMID: 35413951
Immune checkpoint inhibitors are associated with immune-related adverse events (irAEs), including arthritis (arthritis-irAE). Management of arthritis-irAE is challenging because immunomodulatory therapy for arthritis should not impede antitumor immunity. Understanding of...
6.
Maraka S, Groves M, Mammoser A, Melguizo-Gavilanes I, Conrad C, Tremont-Lukats I, et al.
Cancer
. 2018 Oct;
125(3):424-433.
PMID: 30359477
Background: Repurposed memantine, mefloquine, and metformin have putative anticancer activity. The objective of this phase 1 study was to determine the maximum tolerated doses (MTDs) of combinations of these agents...
7.
Neelapu S, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke F, et al.
Nat Rev Clin Oncol
. 2017 Sep;
15(1):47-62.
PMID: 28925994
Immunotherapy using T cells genetically engineered to express a chimeric antigen receptor (CAR) is rapidly emerging as a promising new treatment for haematological and non-haematological malignancies. CAR-T-cell therapy can induce...
8.
Weathers S, Han X, Liu D, Conrad C, Gilbert M, Loghin M, et al.
J Neurooncol
. 2016 Jul;
129(3):487-494.
PMID: 27406589
Antiangiogenic therapy can rapidly reduce vascular permeability and cerebral edema but high doses of bevacizumab may induce selective pressure to promote resistance. This trial evaluated the efficacy of low dose...
9.
Kamiya-Matsuoka C, Paker A, Chi L, Youssef A, Tummala S, Loghin M
J Neurooncol
. 2016 Feb;
128(1):75-84.
PMID: 26900076
Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiologic entity. Its management and outcome in the oncology population is limited because it is still difficult to identify despite an increasingly recognized...
10.
Rapp S, Case L, Peiffer A, Naughton M, Chan M, Stieber V, et al.
J Clin Oncol
. 2015 Apr;
33(15):1653-9.
PMID: 25897156
Purpose: Neurotoxic effects of brain irradiation include cognitive impairment in 50% to 90% of patients. Prior studies have suggested that donepezil, a neurotransmitter modulator, may improve cognitive function. Patients And...